Fresenius Medical Care AG's revenue for the
three
months ended in Mar. 2026 was €4,612 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €19,358 Mil.
Fresenius Medical Care AG's Revenue per Share for the
three
months ended in Mar. 2026 was €16.76.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €67.55.
During the past 12 months, the average Revenue per Share Growth Rate of Fresenius Medical Care AG was 1.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Fresenius Medical Care AG's highest 3-Year average Revenue per Share Growth Rate was 22.30% per year. The lowest was -18.10% per year. And the median was 6.10% per year.
Fresenius Medical Care AG (CHIX:FMEd) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's Revenue distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19,358 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG (CHIX:FMED) has a Revenue of €19,358 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Fresenius Medical Care AG and its competitors.
Is Fresenius Medical Care AG's Revenue too high?
Fresenius Medical Care AG's current Revenue is €19,358 Mil. Overall, Fresenius Medical Care AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's Revenue compare to HCA and THC?
Fresenius Medical Care AG's Revenue of €19,358 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Fresenius Medical Care AG and its competitors. Fresenius Medical Care AG's current Revenue is €19,358 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (CHIX:FMED) is currently considered Fairly Valued. The stock's GF Value™ is €41.35, compared to a current price of €40.03 — trading 3.2% below its estimated fair value. The current Revenue is €19,358 Mil. Fresenius Medical Care AG's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Fresenius Medical Care AG (CHIX:FMED), the current Revenue is €19,358 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (CHIX:FMED) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be undervalued.
The current stock price of €40.03 is trading 3.2% below its estimated GF Value™ of €41.35.
GuruFocus considers Fresenius Medical Care AG to be Fairly Valued.
Key valuation signals for CHIX:FMED:
Revenue: €19,358 Mil
GF Value™: €41.35 vs. price of €40.03 (3.2% below fair value)
No single metric tells the full story. See the CHIX:FMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
69GF Score
Get the complete analysis for CHIX:FMED
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FMED has been successfully added to your 
